Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 626.60, up by 3.30 points or 0.53 % from its previous closing of Rs. 623.30 on the BSE.

The scrip opened at Rs. 621.40 and has touched a high and low of Rs. 628.65 and Rs. 620.25 respectively. So far 43381 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 650.00 on 10-Oct-2013 and a 52 week low of Rs. 393.35 on 01-Mar-2013.

Last one week high and low of the scrip stood at Rs. 626.25 and Rs. 602.00 respectively. The current market cap of the company is Rs. 129095.65 crore.

The promoters holding in the company stood at 63.65 % while Institutions and Non-Institutions held 28.23 % and 8.11 % respectively.

Sun Pharmaceutical Industries has been reported to have received US Food and Drug Administration (USFDA)’s approval to sell a drug to treat Osteoporosis, a bone-weakening disease. Currently the drug, Ibandronate Sodium, is marketed by Roche under the brand name Bovina.

Bovina generated annual sales of $82 million in 2012. Further, Sun pharma is the only generic player to have final approval for this product as many other players would be able to sell the drug after its patent expiry on September 2, 2014.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.